Executive SummaryAdditional dose ranging studies of between 0.2 and 2.0 milligrams of the cancer imaging agent OncoScint are under way and, upon successful completion, will be followed by expanded trials in colorectal cancer patients, Cytogen reports. FDA asked for the additional studies at a mid-August meeting ("The Pink Sheet" Sept. 5, T&G-5)....
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.